Evidence map›Paper›PMID 34055408›Full record

ReviewCritical care research and practice2021

Impact of Adjuvant Use of Midodrine to Intravenous Vasopressors: A Systematic Review and Meta-Analysis.

Ahmad Al-Abdouh, Sadam Haddadin, Atul Matta, Ahmad Jabri, Mahmoud Barbarawi, Waiel Abusnina, Qais Radideh, Mohammed Mhanna, Dante A Suffredini, Erin D Michos

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Critical care research and practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ahmad Al-AbdouhDepartment of Medicine, Ascension Saint Agnes Hospital, Baltimore, MD, USA.ORCID https://orcid.org/0000-0002-2836-0687
Sadam HaddadinDepartment of Medicine, Ascension Saint Agnes Hospital, Baltimore, MD, USA.
Atul MattaDepartment of Pulmonary, Critical Care and Sleep Medicine, Einstein Medical Center, Philadelphia, PA, USA.
Ahmad JabriDepartment of Cardiology, MetroHealth Medical Center, Cleveland, OH, USA.
Mahmoud BarbarawiDepartment of Cardiology, University of Connecticut, Farmington, Mansfield, CT, USA.
Waiel AbusninaDepartment of Cardiology, Creighton University School of Medicine, Omaha, NE, USA.
Qais RadidehMidwest Cardiovascular Research Foundation, Davenport, IA, USA.
Mohammed MhannaDepartment of Medicine, University of Toledo, Toledo, OH, USA.ORCID https://orcid.org/0000-0003-1443-7177
Dante A SuffrediniSection of Critical Care, Department of Medicine, Ascension Saint Agnes Hospital, Baltimore, MD, USA.
Erin D MichosDivision of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Funding

Clinical and Translational Science Collaborative of ClevelandUL1TR002548 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI MCCOMSEY, GRACE A · 2018 to 2022
$35.5M
NCATS NIH HHS UL1 TR002548
6 · The paper itself

Abstract

purposeTo evaluate the efficacy and safety of midodrine use in intensive care units (ICU) to facilitate weaning off intravenous vasopressors (IVV).

methodsWe searched PubMed/MEDLINE, Cochrane library, and Google Scholar (inception through October 18

resultsA total of 6 studies were found that met inclusion criteria and had sufficient data for our quantitative analysis (1 randomized controlled trial and 5 retrospective studies). A total of 2,857 patients were included: 600 in the midodrine group and 2,257 patients in the control group. Midodrine use was not associated with a significant difference in ICU LOS (SMD 0.16 days; 95% CI -0.23 to 0.55), hospital LOS (SMD 0.03 days; 95% CI -0.33 to 0.0.39), mortality (RR 0.87; 95% CI 0.52 to 1.46), IVV reinstitution (RR 0.47; 95% CI 0.17 to 1.3), or ICU readmission (RR 1.03; 95% CI 0.71 to 1.49) when compared to using only IVV. However, there were higher trends of bradycardia with midodrine use that did not reach significance (RR 7.64; 95% CI 0.23 to 256.42).

conclusionThis meta-analysis suggests that midodrine was not associated with a significant decrease in ICU LOS, hospital LOS, mortality, or ICU readmissions.

Identifiers

PMID34055408
PMCPMC8147551

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.